Program
Everolimus
Also written as “everolimus”, “RAD001” and “Everolimus (RAD001)”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Tuberous Sclerosis · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 1201 open or running | phase 4since Sep 8, 2005 | Oct 6, 2004 | Feb 26, 2027phase 3 · NCT02962414 |
| Chong Kun Dang Pharmaceutical | 21 open or running | phase 4since Apr 29, 2021 | Apr 29, 2021 | Dec 2030phase 4 · NCT06942156 |
| iOMEDICO | 20 open or running | phase 4since Dec 23, 2010 | Dec 23, 2010 | none ahead |
| Chiesi Farmaceutici | 10 open or running | phase 2since Oct 28, 2016 | Oct 28, 2016 | none ahead |
Also a collaborator on its studies: Merck, Pfizer, cromsource and roche-pharma-ag.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 2, 2009.
- Feb 20, 2014Phase 2 study in Advanced Breast CancerNovartis · NCT02069093 · 92 enrolled · United States
- Mar 20, 2014Phase 3 study in Liver TransplantationNovartis · NCT02115113 · 78 enrolled · Italy
- Aug 28, 2014Phase 4 study in Breast NeoplasmsiOMEDICO · NCT02248571 · 85 enrolled · Germany
- Dec 1, 2014Phase 4 study in Body WeightNovartis · NCT02338609 · 15 enrolled · United States, Belgium, Russian Federation
- Jun 1, 20162 phase 4 studiesNovartis · NCT02864706, NCT02842749
- Oct 28, 2016Chiesi Farmaceutici's first study: phase 2 study in Kidney TransplantationNew to Chiesi FarmaceuticiChiesi Farmaceutici · NCT02970630 · 28 enrolled · Italy
- Nov 9, 2016Phase 3 study in Tuberous SclerosisNovartis · NCT02962414 · 206 enrolled · United States, Australia, Belgium and more
- Jun 1, 2017Phase 3 study in Breast NeoplasmsNovartis · NCT03176238 · 235 enrolled · Australia, India, Indonesia and more
- Sep 15, 2017Phase 2 study in Breast NeoplasmsNovartis · NCT03312738 · 159 enrolled · China
- May 3, 2018Phase 4 study in AngiomyolipomaNovartis · NCT03525834 · 40 enrolled · China
- Apr 29, 2021Chong Kun Dang Pharmaceutical's first study: phase 4 study in Liver TransplantNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT04867720 · 112 enrolled · Korea, Republic of
- Feb 16, 2022Phase 4 study in AngiomyolipomaNovartis · NCT05252585 · 10 enrolled · Taiwan
- Apr 11, 2025Phase 4 study in Heart TransplantChong Kun Dang Pharmaceutical · NCT06942156 · 140 planned · Korea, Republic of
- Nov 12, 2026Primary completion moved from 2026-12-30 to 2027-02-26Date moved laterphase 3 · +2 months · NCT02962414
Ahead
- Feb 26, 2027Primary completion: phase 3 study in Tuberous SclerosisNovartis · NCT02962414
- Dec 2030Primary completion: phase 4 study in Heart TransplantChong Kun Dang Pharmaceutical · NCT06942156
TargetBeta
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule
Other programs on FKBP1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tacrolimusrule | Astellas Pharma | phase 4 | 182 |
Studies
The newest 60 of 125 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06942156Heart Transplant · Korea, Republic of | 4 | Not yet recruiting | Chong Kun Dang Pharmaceutical | Dec 2030 | 140 |
| NCT05252585Angiomyolipoma · Taiwan | 4 | Completed | Novartis | Oct 13, 2026 | 10 |
| NCT04867720Liver Transplant · Korea, Republic of | 4 | UNKNOWN | Chong Kun Dang Pharmaceutical | Oct 10, 2022 | 112 |
| NCT03525834Angiomyolipoma · China | 4 | Completed | Novartis | Sep 25, 2020 | 40 |
| NCT03312738Breast Neoplasms · China | 2 | Completed | Novartis | Apr 25, 2022 | 159 |
| NCT03176238Breast Neoplasms · Australia, India, Indonesia and more | 3 | Completed | Novartis | Jan 29, 2019 | 235 |
| NCT02962414Tuberous Sclerosis · United States, Australia, Belgium and more | 3 | Active, not recruiting | Novartis | Feb 26, 2027 | 206 |
| NCT02970630Kidney Transplantation · Italy | 2 | Completed | Chiesi Farmaceutici | Feb 22, 2018 | 28 |
| NCT02842749Pancreatic Neuroendocrine Tumors · China | 4 | Completed | Novartis | Feb 22, 2024 | 61 |
| NCT02864706Graft vs Host Disease · Denmark, Norway, Sweden | 4 | Completed | Novartis | Sep 25, 2017 | 95 |
| NCT02338609Body Weight · United States, Belgium, Russian Federation | 4 | Completed | Novartis | Dec 18, 2023 | 15 |
| NCT02248571Breast Neoplasms · Germany | 4 | Completed | iOMEDICO | Aug 31, 2017 | 85 |
| NCT02115113Liver Transplantation · Italy | 3 | Completed | Novartis | Sep 30, 2016 | 78 |
| NCT02069093Advanced Breast Cancer · United States | 2 | Completed | Novartis | Mar 2016 | 92 |
| NCT02017860Neoplasms · Japan | 2 | Completed | Novartis | Apr 25, 2019 | 4 |
| NCT01843348Rejection, Psychology · France, Germany | 3 | Completed | Novartis | Mar 23, 2016 | 612 |
| NCT01789281Neoplasms · United States, Czechia, Italy and more | 4 | Completed | Novartis | Aug 28, 2020 | 34 |
| NCT01783444Breast Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Novartis | Jul 2, 2018 | 309 |
| NCT01743560Breast Neoplasms · United Kingdom | 4 | Completed | Novartis | Aug 15, 2016 | 52 |
| NCT01713946Tuberous Sclerosis Complex-associated Refractory Seizures · United States, Argentina, Australia and more | 3 | Completed | Novartis | Oct 25, 2017 | 366 |
| NCT01698918Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Completed | Novartis | Dec 17, 2015 | 202 |
| NCT01626222Breast Neoplasms · Germany | 3 | Completed | Novartis | Nov 2013 | 301 |
| NCT01625377Liver Transplantation · France | 3 | Completed | Novartis | Mar 2015 | 188 |
| NCT01595009Neuroendocrine Tumors · Germany | 4 | Completed | Novartis | Aug 9, 2016 | 246 |
| NCT01594268Kidney Transplant · Korea, Republic of | 4 | Completed | Novartis | Oct 2013 | 54 |
| NCT01590199Neuroendocrine Tumors · Germany | 1 | Completed | Novartis | Sep 11, 2018 | 18 |
| NCT01563354Carcinoma, Neuroendocrine · Denmark, France, Germany and more | 2 | Completed | Novartis | Feb 10, 2020 | 124 |
| NCT01551212Liver Transplantation · Germany | 4 | Completed | Novartis | Aug 8, 2017 | 339 |
| NCT01514448Carcinoma, Renal Cell · Germany | 4 | Completed | Novartis | Apr 1, 2016 | 29 |
| NCT01524783Neuroendocrine Tumors · United States, Austria, Belgium and more | 3 | Completed | Novartis | Nov 28, 2014 | 302 |
| NCT01491672Carcinoma, Renal Cell · United States, Argentina, Brazil and more | 2 | Completed | Novartis | May 2015 | 134 |
| NCT01545817Carcinoma, Renal Cell · Australia, Korea, Republic of | 2 | Terminated | Novartis | Nov 18, 2016 | 74 |
| NCT01596062Renal Transplantation · France | 2 | Completed | Novartis | Mar 2013 | 16 |
| NCT01404325Lung Transplantation · Germany | 3 | Completed | Novartis | Jan 5, 2017 | 130 |
| NCT01374451Adenoma, Islet Cell · United States, Argentina, Australia and more | 2 | Terminated | Novartis | Feb 2015 | 160 |
| NCT01544491Death · United States, Argentina, Brazil and more | 3 | Completed | Novartis | Oct 3, 2016 | 106 |
| NCT01379521Carcinoma, Hepatocellular · Hong Kong, Taiwan, Thailand | 2 | Terminated | Novartis | Jun 2015 | 65 |
| NCT01365468Neurofibroma, Plexiform · Israel | 2 | Terminated | Novartis | Apr 2015 | 9 |
| NCT01324492Lung Neuroendocrine Neoplasm · China | 1 | Completed | Novartis | Jun 2014 | 16 |
| NCT01317615Carcinoma, Large Cell · Germany | 4 | Completed | Novartis | Mar 2015 | 49 |
| NCT01275222Gastrointestinal Stromal Tumors · United States, Belgium, France and more | 2 | Completed | Novartis | Sep 3, 2008 | 117 |
| NCT01266837Carcinoma, Renal Cell · Germany | 4 | Completed | iOMEDICO | Sep 26, 2017 | 64 |
| NCT01263353Carcinoid Tumor · Germany | 1 | Completed | Novartis | Mar 2014 | 36 |
| NCT01231659Breast Neoplasms · Israel | 2 | Completed | Novartis | Nov 20, 2012 | 72 |
| NCT01217177Uterine Cervical Neoplasms · Brazil | 1 | Completed | Novartis | Apr 2014 | 14 |
| NCT01269684Kidney Transplantation · Switzerland | 4 | Withdrawn | Novartis | Aug 2008 | 0 |
| NCT01206764Carcinoma, Renal Cell · Algeria, Egypt, India and more | 4 | Completed | Novartis | Jun 6, 2017 | 143 |
| NCT01266148Renal Function and Chronic Allograft Vasculopathy · Denmark, Norway, Sweden | 4 | Completed | Novartis | Dec 2012 | 115 |
| NCT01169701Hypertrophy, Left Ventricular · Spain | 4 | Completed | Novartis | Mar 2014 | 71 |
| NCT01152801Carcinoma, Renal Cell · China | 1 | Completed | Novartis | Dec 2013 | 64 |
| NCT01114529Kidney Transplantation · Argentina, Australia, Austria and more | 3 | Completed | Novartis | Oct 30, 2014 | 828 |
| NCT01150097Liver Transplant Recipient · United States, Argentina, Australia and more | 3 | Completed | Novartis | May 3, 2013 | 284 |
| NCT01079143Renal Interstitial Fibrosis · France | 3 | Completed | Novartis | Jun 2012 | 194 |
| NCT01059318Lymphangioleiomyomatosis · United States, France, Italy | 2 | Completed | Novartis | Jun 2012 | 24 |
| NCT01035229Carcinoma · United States, Australia, Austria and more | 3 | Completed | Novartis | Oct 2013 | 546 |
| NCT01023815de Novo Kidney Transplant Recipients · Italy | 3 | Completed | Novartis | Jul 2012 | 330 |
| NCT01022996Hodgkin Disease · United States | 2 | Completed | Novartis | Nov 2014 | 57 |
| NCT01025817Kidney Transplant · United States, Canada | 3 | Completed | Novartis | Mar 2013 | 613 |
| NCT01017029Cardiac Transplantation · Italy | 4 | Completed | Novartis | Dec 2013 | 182 |
| NCT01007942Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Novartis | Jun 2015 | 569 |
How it is read
Names in the registry
- “Everolimus”, 64 entries
- “everolimus”, 16 entries
- “RAD001”, 16 entries
- “Everolimus (RAD001)”, 15 entries
- “Everolimus (reduced tacrolimus)”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 17 studies
- Carcinoma, Renal Cell, 12 studies
- Tuberous Sclerosis, 5 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Neuroendocrine Tumors, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.